| 0 | 💬 0 |
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults >/=60 Years of Age.
(academic.oup.com)
|
Journal of Infectious Diseases 2026-07-09 | #vaccination #immunogenicity #rsv #rna #safety |